Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181


High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.

Tanton C, Soldan K, Beddows S, Mercer CH, Waller J, Field N, Clifton S, Copas AJ, Panwar K, Manyenga P, da Silva F, Wellings K, Ison CA, Johnson AM, Sonnenberg P.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):842-53. doi: 10.1158/1055-9965.EPI-14-1333. Epub 2015 Mar 3.


Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, Mercer CH, da Silva FC, Alexander S, Copas AJ, Phelps A, Erens B, Prah P, Macdowall W, Wellings K, Ison CA, Johnson AM.

Lancet. 2013 Nov 30;382(9907):1795-806. doi: 10.1016/S0140-6736(13)61947-9. Epub 2013 Nov 26.


The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.

Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG.

J Epidemiol Community Health. 2017 Oct;71(10):954-960. doi: 10.1136/jech-2017-209113. Epub 2017 Jul 29.


Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study.

Johnson HC, Lafferty EI, Eggo RM, Louie K, Soldan K, Waller J, Edmunds WJ.

Lancet Public Health. 2018 Jan;3(1):e44-e51. doi: 10.1016/S2468-2667(17)30238-4. Epub 2017 Dec 19.


The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.


Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.

Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.

J Clin Pathol. 2015 Feb;68(2):135-40. doi: 10.1136/jclinpath-2014-202681. Epub 2014 Nov 19.


The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.


Racial and Ethnic Group Knowledge, Perceptions and Behaviors about Human Papillomavirus, Human Papillomavirus Vaccination, and Cervical Cancer among Adolescent Females.

Bond SM, Cartmell KB, Lopez CM, Ford ME, Brandt HM, Gore EI, Zapka JG, Alberg AJ.

J Pediatr Adolesc Gynecol. 2016 Oct;29(5):429-435. doi: 10.1016/j.jpag.2016.02.005. Epub 2016 Feb 22.


Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.

J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. doi: 10.1093/jnci/djn510. Epub 2009 Mar 24.


Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

Adams M, Jasani B, Fiander A.

Vaccine. 2007 Apr 20;25(16):3007-13. Epub 2007 Jan 18. Review.


How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.


Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.

Borena W, Grünberger M, Widschwendter A, Kraxner KH, Marth E, Mayr P, Meier J, Ruth N, Guerrero AT, Marth C, Holm-von Laer D.

BMC Public Health. 2016 Aug 26;16:889. doi: 10.1186/s12889-016-3581-0.


Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.

Ngabo F, Franceschi S, Baussano I, Umulisa MC, Snijders PJ, Uyterlinde AM, Lazzarato F, Tenet V, Gatera M, Binagwaho A, Clifford GM.

BMC Infect Dis. 2016 May 24;16:225. doi: 10.1186/s12879-016-1539-6.


Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain.

Johnson AM, Mercer CH, Beddows S, de Silva N, Desai S, Howell-Jones R, Carder C, Sonnenberg P, Fenton KA, Lowndes C, Soldan K.

Sex Transm Infect. 2012 Apr;88(3):212-7. doi: 10.1136/sextrans-2011-050306. Epub 2012 Jan 17.


Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland.

Riesen M, Garcia V, Low N, Althaus CL.

Vaccine. 2017 Dec 19;35(52):7312-7321. doi: 10.1016/j.vaccine.2017.10.103. Epub 2017 Nov 7.


Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.


HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.


Supplemental Content

Support Center